17 research outputs found
Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial
Background: The microorganism present in breast milk, added to other factors, determine the colonization of
infants. The objective of the present study is to evaluate the safety, tolerance and effects of the consumption of a
milk formula during the first year of life that is supplemented with L. fermentum CECT5716 or Bifidobacterium breve
CECT7263, two strains originally isolated from breast milk. Results: One hundred and eighty-nine infants completed the eleven months of intervention (61 in control group,
65 in Lf group and 63 in Bb group). The growth of infants in the three groups was consistent with standards. No
significant differences were observed in the main outcome, weight-gain (Control group: 5.77 Kg ± 0.95, Lf group:
5.77 Kg ± 1.31, Bb group: 5.58 Kg ± 1.10; p = 0.527). The three milk formulae were well tolerated, and no adverse
effects were related to the consumption of any of the formula. Infants receiving B. breve CECT7263 had a 1.7 times
lower risk of crying than the control group (OR = 0.569, CI 95% 0.568–0.571; p = 0.001). On the other hand, the
incidence of diarrhoea in infants receiving the formula supplemented with L. fermentum CECT5716 was a 44%
lower than in infants receiving the control formula (p = 0.014). The consumption of this Lactobacillus strain also
reduced the duration of diarrhoea by 2.5 days versus control group (p = 0.044).
Conclusions: The addition of L. fermentum CECT5716 Lc40 or B. breve CECT7263, two probiotic strains naturally
found in breast milk, to infant formulae is safe and induces beneficial effects on the health of infants.This work was funded by Biosearch Life supported by a grant from the
Agency of Innovation and Development of Andalusia (IDEA-Spain), Cofinanced
by European Regional Development Fund (EC). Project Tittle: “New
applications of probiotic strains and derived compounds with biological activity
(POSTBIO)” and partially funded by Lactalis-Puleva (Granada, Spain)
Natural History of MYH7-Related Dilated Cardiomyopathy
BACKGROUND: Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described. OBJECTIVE: We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression. METHODS: We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 ± 19.2 years) recruited from 29 international centers. RESULTS: At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% ± 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of ≤35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants. CONCLUSIONS: MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare
Natural History of MYH7-Related Dilated Cardiomyopathy
BACKGROUND Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described. OBJECTIVES We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression. METHODS We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 +/- 19.2 years) recruited from 29 international centers. RESULTS At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% +/- 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of <= 35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants. CONCLUSIONS MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation
Caracteres morfológicos de plantas de Morus alba L. derivadas del cultivo in vitro en condiciones de campo
Se evaluaron en condiciones de campo plantas de morera provenientes del cultivo in vitro desarrolladas en medio de cultivo semisólido, inmersión temporal y plantas, control en dos localidades con diferencias en tipo de suelo y método de riego. Se utilizó un arreglo factorial 2x3 con 4 repeticiones por tratamiento. Se determinó el porcentaje de supervivencia, altura de la planta, número de hojas y tallos, acumulación de materia seca y tasa de crecimiento. Se observó un mejor comportamiento de las plantas en la localidad 1 con valores de 97.51%, 106.79 cm, 230.05 hojas, 7.97 tallos, 1256.4 kg ha-1 y 9.62 kg MS ha-1 día-1, respectivamente para las variables evaluadas, respecto a la localidad 2; asimismo, las plantas in vitro fueron superiores a las plantas control y entre estas, las plantas procedentes de inmersión temporal superaron a las de medio de cultivo semisólido
Caracteres morfológicos de plantas de Morus alba L. derivadas del cultivo in vitro en condiciones de campo
Se evaluaron en condiciones de campo plantas de morera provenientes del cultivo in vitro desarrolladas en medio de cultivo semisólido, inmersión temporal y plantas, control en dos localidades con diferencias en tipo de suelo y método de riego. Se utilizó un arreglo factorial 2x3 con 4 repeticiones por tratamiento. Se determinó el porcentaje de supervivencia, altura de la planta, número de hojas y tallos, acumulación de materia seca y tasa de crecimiento. Se observó un mejor comportamiento de las plantas en la localidad 1 con valores de 97.51%, 106.79 cm, 230.05 hojas, 7.97 tallos, 1256.4 kg ha-1 y 9.62 kg MS ha-1 día-1, respectivamente para las variables evaluadas, respecto a la localidad 2; asimismo, las plantas in vitro fueron superiores a las plantas control y entre estas, las plantas procedentes de inmersión temporal superaron a las de medio de cultivo semisólido
OC-0398: HSPB1 rs2868370 predicts risk of relapse in patients with lung cancer treated with radio(chemo)therapy
Cyclical salt efflorescence weathering: an invisible threat to the recovery of underground mine environment for tourist exploitation
Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group
Natural History of MYH7-Related Dilated Cardiomyopathy.
Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described.
We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression.
We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 ± 19.2 years) recruited from 29 international centers.
At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% ± 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of ≤35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants.
MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare.This study has been funded by Instituto de Salud Carlos III (ISCIII)
through the projects PI18/0004, PI20/0320, and PT17/0015/0043
(cofunded by European Regional Development Fund/European Social
Fund “A way to make Europe”/“Investing in your future”). The
Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo
Ochoa Centers of Excellence program (CEX2020-001041-S). The
Hospital Universitario Puerta de Hierro, the Hospital Sant Joan de
Déu, and the Hospital Universitario Virgen de la Arrixaca are members of the European Reference Network for Rare and Low Prevalence
Complex Diseases of the Heart. Dr de Frutos receives grant support
from ISCIII (CM20/00101). Genetic examinations of Polish patients
were funded with DETECTIN-HF grant from the ERA-CVD framework,
NCBiR. Dr Baas has received funding from CVON2020B005 DOUBLEDOSE, Dutch Heart Foundation (Dekker 2015T041). Dr Fatkin has
received funding from Victor Chang Cardiac Research Institute and
NSW Health. Dr Lopes is funded by an MRC UK Clinical Academic
Research Partnership award (MR/T005181/1). Dr Meder has received
funding from the Deutsches Zentrum für Herz-Kreislauf-Forschung
(German Center for Cardiovascular Research) and Informatics for
Life (Klaus Tschira Foundation). Dr Kubanek has received grant
support from the Ministry of Health, Czech Republic (NV19-08-00122)
and IPO (Institute for Clinical and Experimental Medicine–IKEM, IN
00023001). All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.S